Skip to main content
. 2024 Apr 30;121(19):e2321438121. doi: 10.1073/pnas.2321438121

Fig. 3.

Fig. 3.

Myospreader improves Cas9 editing efficiency in vivo. (A) Schematic of the experiment to measure the efficacy of AAVs containing 2xSV40 NLS Cas9 or Myospreader Cas9, systemically delivered to 4-wk-old Ai14 mice at a dose of 5E+13 vg/kg. (B) tdTomato mRNA expression as assessed by RT-qPCR in muscles of treated Ai14 mice. Plotted relative to the mean of the 2xSV40 NLS Cas9 group. Significance by Student’s t test. (C) Cas9 mRNA expression as assessed by RT-qPCR in muscles of treated Ai14 mice. Plotted relative to the mean of the 2xSV40 NLS Cas9 group. Significance by Student’s t test. (D) Representative images of tdTomato fluorescence (red) and DAPI (blue) in muscles of treated Ai14 mice. (Scale bar: 100 µm.) (E) Quantification of Tdtomato protein as determined by western blot/densitometry, normalized to Gapdh. Plotted relative to the mean of the 2xSV40 NLS Cas9 group. Significance by Student’s t test. (F) Quantification of Cas9 protein as determined by western blot/densitometry, normalized to Gapdh. Plotted relative to the mean of the 2xSV40 NLS Cas9 group. Significance by Student’s t test (ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001) (error bars = 95% CI).